PharmiWeb Recruiter Blog

Parexel

Global Investigative Sites Recognize Parexel with the 2023 Society for Clinical Research Sites Eagle Award

DURHAM, N.C., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, today announced it has been awarded the 2023 Society for Clinical Research Sites (SCRS) Eagle Award (CRO category). Parexel received the award at the annual Global Site Solutions Summit held Oct. 6-8 in Hollywood, Fla. The SCRS Eagle Award recognizes the sponsor and CRO committed to outstanding leadership, professionalism, integrity, passion and dedication to advancing the clinical research profession through strong site partnerships.

Read more

Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics

  • Bristol Myers Squibb to Acquire Mirati for $58.00 Per Share, Representing $4.8 Billion Equity Value and Up to $5.8 Billion Including the Contingent Value Right Acquisition Brings KRAZATI® (adagrasib), a Best-in-Class KRASG12C Inhibitor Approved by the U.S. FDA for the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring a KRASG12C Mutation and Who Have Received at Least One Prior Systemic Treatment
  • KRAZATI is in Clinical Development in Combination with a PD-1 Inhibitor as a First-Line Therapy for Patients with Non-Small Cell Lung Cancer Harboring a KRASG12C Mutation as well as in Other Indications
  • Mirati’s Promising Pipeline Includes a Potent Selective PRMT5/MTA Inhibitor, MRTX1719, a Potential First-in-Class and Best-in-Class Asset; and Early Clinical Pipeline Features a KRAS and KRAS Enabling Program, including MRTX1133, and a SOS1 Inhibitor, MRTX0902

PRINCETON, N.J. & SAN DIEGO--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) and Mirati Therapeutics, Inc.® (NASDAQ: MRTX) today announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Mirati for $58.00 per share in cash, for a total equity value of $4.8 billion. Mirati stockholders will also receive one non-tradeable Contingent Value Right (CVR) for each Mirati share held, potentially worth $12.00 per share in cash, representing an additional $1.0 billion of value opportunity. The transaction was unanimously approved by both the Bristol Myers Squibb and the Mirati Boards of Directors.

Read more
Allergan Aesthetics

Allergan Aesthetics and Girls Inc. Partner to Speed the Entry of Young Women into Positions of Leadership in the STEM Field

  • Girls Inc. alumnae in New York, San Antonio and Central Alabama will participate in a virtual panel titled 'Equipping the New Generation of STEM Leaders' with leading women physicians sharing their career journeys including growth moments and challenges
  • A social media campaign shares authentic stories and aspirations of girls entering the workforce

IRVINE, Calif., Oct. 3, 2023 /PRNewswire/ -- Today Allergan Aesthetics, an AbbVie company, announces its fifth year of partnership with Girls Inc., this year supporting Project Accelerate, a program addressing inequality in the workplace that aims to accelerate young women's trajectories through college and career entry. The Allergan Aesthetics effort will focus specifically on leadership paths in STEM (science, technology, engineering, and math).

Read more
5 Ways Skills-Based Hiring Can Transform Your Recruitment

5 Ways Skills-Based Hiring Can Transform Your Recruitment

In today’s competitive job market, traditional hiring methods often struggle to keep pace with the evolving needs of the life science industry. Faced with an ever-increasing talent shortage, now is the time to explore new approaches to talent acquisition that will help to expand your talent pool, streamline your recruitment process, and improve employee engagement and retention.

Read more